Incyte Cancels Phase 3 Trial of Ovarian Cancer Candidate INCB123667
Incyte Corp. (INCY) has announced its decision to discontinue the phase 3 MAESTRA-3 clinical trial, which was scheduled to commence this quarter. The study was intended to evaluate the efficacy of INCB123667 in combination with Avastin (bevacizumab) as a first-line maintenance therapy for patients with ovarian cancer. The cancellation represents a setback for Incyte's oncology pipeline development regarding this specific asset. Investors will likely monitor how this decision affects the company's long-term clinical roadmap and its strategic focus on other therapeutic areas.
Tickers: $INCY
Topics: clinical trial discontinuation drug development ovarian cancer
Read the full article at Seeking Alpha
Part of the story INCYTE CORP - 8-K Filing (2 articles)